重药控股(000950.SZ)：盐酸普拉格雷片获临床试验批准

Core Viewpoint - Chongqing Pharmaceutical (Group) Co., Ltd., a subsidiary of Zhongyao Holdings, has received approval from the National Medical Products Administration for clinical trials of Prasugrel Hydrochloride Tablets, marking a significant step in expanding its product portfolio in the cardiovascular drug market [1]. Company Summary - Zhongyao Holdings' subsidiary, Chongqing Pharmaceutical, has been granted a clinical trial approval for Prasugrel Hydrochloride Tablets by the National Medical Products Administration [1]. - Prasugrel Hydrochloride is a third-generation drug that inhibits ADP-induced platelet aggregation, aimed at preventing thrombus formation in patients undergoing percutaneous coronary intervention for acute coronary syndrome, stable angina, and old myocardial infarction [1]. - The original developer of Prasugrel is Daiichi Sankyo Co., Ltd., and the drug is currently available in over 70 countries and regions worldwide, although it has not yet been launched in China [1].